Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: Experience from Singapore
10.3760/cma.j.cn441530-20250410-00151
- VernacularTitle:腹腔内化疗在胃癌腹膜转移治疗中的应用——新加坡经验
- Author:
Tan Yu CHUAN
1
Author Information
1. 上海交通大学医学院附属瑞金医院创面修复中心
- Collective Name:Chia Daryl Kai Ann;So Jimmy Bok Yan
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Peritoneal metastasis;
Intraperitoneal chemotherapy;
Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
- From:
Chinese Journal of Gastrointestinal Surgery
2025;28(5):493-496
- CountryChina
- Language:Chinese
-
Abstract:
Systemic chemotherapy currently remains the standard treatment for gastric cancer with peritoneal metastasis (GCPM). However, the plasma-peritoneum barrier significantly limits drug penetration into the peritoneal cavity, resulting in the poor prognosis for GCPM patients. In Singapore, intraperitoneal chemotherapy has been demonstrated as a safe and effective approach for GCPM treatment following the implementation of various modalities including pressurized intraperitoneal aerosol chemotherapy (PIPAC), catheter-based intraperitoneal (IP) chemotherapy and conventional hyperthermic intraperitoneal chemotherapy (HIPEC). This article reviews the evolution of intraperitoneal chemotherapy in Singapore and highlights several important clinical trials. Looking forward, the bidirectional approach combining intraperitoneal and systemic chemotherapy will be further refined through the integration of novel drug combinations, optimization of delivery techniques, and expansion of clinical research.
